DAY 1

DAY 2

Speakers 2022

PROGRAM

2 DAYS OF HIGH LEVEL CONFERENCES

The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.

CAR-T CELLS

Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the revolutionized the disease course of patients with refractory/resistant refractory/resistant hematological malignancies. Based on these these unexpected and impressive results, the world of immunotherapy cellular immunotherapy offers new perspectives.

This session will cover a wide range of topics from research to understand mechanisms, production with alternative cell sources, to the clinic with feedbacks from the specific Spanish and from the productive Chinese models. Clinical management of innovative drugs in real life will also be discussed.

Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.

RNA

RNA is the basis for numerous therapeutic product manufacturing. Biologics, recombinant proteins, gene-modified cells, vaccines… all of these innovative therapies are somehow dependent on RNA. This session will cover different aspects of RNA manufacturing and applications in several settings like vaccines and biologics.

UPCOMING INNOVATIVE THERAPIES

This session will gather experts in the development of new cell therapies to the clinic.
Speakers will give us feedback on difficulties and successes, and their view on the future of such approaches to ameliorate patients’ care.

REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES

This session will give exemples of the ATMP production ecosystem, with pre-industrial and industrial structures, and the challenges of financing these therapies.

We will also have a presentation of the regulatory guidelines defined for ATMPs and the new European regulation on clinical trials, by the European Medicines Agency and by the CAT (French Committee for Advanced Therapy Products).

Thursday, October 12th

PROGRAM IN PROGRESS

Friday, October 13th

PROGRAM IN PROGRESS

Join us and meet our speakers

Pr Olivier ADOTEVI – Right Institute (Besançon, FR), Dr Marco ALESSANDRINI – Antion Biosciences (Geneva, CH), Pascale BOUILLÉ – Flash Therapeutics (Toulouse, FR), Dr Philippe BOUSSO – Institut Pasteur (Paris, FR), Emmanuel DEQUIER – « Grand défi Biomedicaments » (Paris, FR), Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Pr Olivier DETANTE – Grenoble Institute of Neurosciences (Grenoble, FR), Dr Philippe DULIEU – RD Biotech (Besançon, FR), Dr Céline ELIE-CAILLE –FEMTO-ST Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Dr Miguel FORTE – Bone Therapeutics (Charleroi, BE), Claire GERARD – Agence nationale de sécurité du médicament et des produits de santé, ANSM (Lyon, FR), Dr Mathilde GIRARD – ADHARA, subsidiary of the URGO Group (Chenôve, FR), Dr Mathieu GUERRIAUD – CREDIMI (Dijon, FR), Eric HALIOUA– PDC*line Pharma (Liège-Belgium), Dr Carole HENRY – Moderna Cambridge (Massachusetts, USA), Pr Roch HOUOT – UMR INSERM U1236 (Rennes, FR), Pr HUANG HE – Institute of Hematology, Zhejiang University (Hangzhou, PRC), Nathalie LABARRIERE – INCIT, UMR 1302 (Nantes, FR), Dr Suman MITRA  INSERM (Lille, FR), Sylvain PERRUCHE – RIGHT Institute (Besançon, FR), Pr Marco RUELLA – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA), Phil CHALLIS – eTheRNA immunotherapies NV (Niel, Belgium),  Dr Álvaro URBANO ISPIZUA – Clínic de Barcelona (Barcelona, SP), Julien VALTON – Cellectis (Paris, FR), Dr Andreas WALLNÖFER – Jeito Capital (Paris, FR)

Speakers